Fall of the mutants: T cells targeting BCR-ABL

Premal Lulla, Helen Heslop

Research output: Contribution to journalComment/debate

3 Scopus citations

Abstract

Targeting the tumor-specific junction sequence produced by the BCR-ABL fusion has long been an attractive strategy and, in this issue of Blood, Comoli et al demonstrate, for the first time in humans, clinical benefit with infusions of p190BCR-ABL neoantigen-specific T cells to 3 patients with active Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).1.

Original languageEnglish (US)
Pages (from-to)539-540
Number of pages2
JournalBlood
Volume129
Issue number5
DOIs
StatePublished - Feb 2 2017

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Fall of the mutants: T cells targeting BCR-ABL'. Together they form a unique fingerprint.

Cite this